Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.

PubMed  Google Scholar 

Park EH, Jung KW, Park NJ, Kang MJ, Yun EH, Kim HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2022. Cancer Res Treat. 2025;57(2):312–30.

Article  PubMed  PubMed Central  Google Scholar 

Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022;603(7903):942–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boku N. HER2-positive gastric cancer. Gastric Cancer. 2014;17(1):1–12.

Article  CAS  PubMed  Google Scholar 

Hayes DF. HER2 and breast cancer - a phenomenal success story. N Engl J Med. 2019;381(13):1284–6.

Article  PubMed  Google Scholar 

Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382(25):2419–30.

Article  CAS  PubMed  Google Scholar 

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.

Article  CAS  PubMed  Google Scholar 

Pohlmann PR, Mayer IA, Mernaugh R. Resistance to Trastuzumab in breast cancer. Clin Cancer Res. 2009;15(24):7479–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nam AR, Kim JW, Park JE, Bang JH, Jin MH, Oh DY, et al. Jab1 silencing inhibits proliferation and sensitizes to Cisplatin in biliary tract cancer. Cancer Res Treat. 2019;51(3):886–900.

Article  CAS  PubMed  Google Scholar 

Cope GA, Suh GS, Aravind L, Schwarz SE, Zipursky SL, Koonin EV, et al. Role of predicted metalloprotease motif of Jab1/Csn5 in cleavage of Nedd8 from Cul1. Science. 2002;298(5593):608–11.

Article  CAS  PubMed  Google Scholar 

Tsherniak A, Vazquez F, Montgomery PG, Weir BA, Kryukov G, Cowley GS, et al. Defining a cancer dependency map. Cell. 2017;170(3):564-76 e16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schlierf A, Altmann E, Quancard J, Jefferson AB, Assenberg R, Renatus M, et al. Targeted inhibition of the COP9 signalosome for treatment of cancer. Nat Commun. 2016;7(1):13166.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rao X, Huang X, Zhou Z, Lin X. An improvement of the 2^(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis. Biostat Biopharm Biomath. 2013;3(3):71–85.

Google Scholar 

Kim KJ, Kim JW, Sung JH, Suh KJ, Lee JY, Kim SH, et al. Pi3k-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer. Sci Rep. 2020;10(1):12308.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Escriva M, Peiro S, Herranz N, Villagrasa P, Dave N, Montserrat-Sentis B, et al. Repression of PTEN phosphatase by Snail1 transcriptional factor during gamma radiation-induced apoptosis. Mol Cell Biol. 2008;28(5):1528–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Uygur B, Abramo K, Leikina E, Vary C, Liaw L, Wu WS. SLUG is a direct transcriptional repressor of PTEN tumor suppressor. Prostate. 2015;75(9):907–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Watanabe K, Yokoyama S, Kaneto N, Hori T, Iwakami Y, Kato S, et al. COP9 signalosome subunit 5 regulates cancer metastasis by deubiquitinating SNAIL. Oncotarget. 2018;9(29):20670–80.

Article  PubMed  PubMed Central  Google Scholar 

Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004;6(2):117–27.

Article  CAS  PubMed  Google Scholar 

Lim SO, Li CW, Xia W, Cha JH, Chan LC, Wu Y, et al. Deubiquitination and stabilization of PD-L1 by CSN5. Cancer Cell. 2016;30(6):925–39.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ma Y-S, Wang X-F, Zhang Y-J, Luo P, Long H-D, Li L, et al. Inhibition of USP14 deubiquitinating activity as a potential therapy for tumors with p53 deficiency. Molecular Therapy-Oncolytics. 2020;16:147–57.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang L, Zeng X, Yang G, Liu G, Pan Y. Pan-cancer analyses of Jab1/COPS5 reveal oncogenic role and clinical outcome in human cancer. Heliyon. 2022;8(12):e12553.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu G, Claret FX, Zhou F, Pan Y. Jab1/COPS5 as a novel biomarker for diagnosis, prognosis, therapy prediction and therapeutic tools for human cancer. Front Pharmacol. 2018;9:135.

Article  PubMed  PubMed Central  Google Scholar 

Yokoyama D, Hisamori S, Deguchi Y, Nishigori T, Okabe H, Kanaya S, et al. PTEN is a predictive biomarker of trastuzumab resistance and prognostic factor in HER2-overexpressing gastroesophageal adenocarcinoma. Sci Rep. 2021;11(1):9013.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Deguchi Y, Okabe H, Oshima N, Hisamori S, Minamiguchi S, Muto M, et al. PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma. Gastric Cancer. 2017;20:416–27.

Article  CAS  PubMed  Google Scholar 

Pietrantonio F, Fucà G, Morano F, Gloghini A, Corso S, Aprile G, et al. Biomarkers of primary resistance to trastuzumab in HER2-Positive metastatic gastric cancer patients: the AMNESIA case-control studyprimary resistance to trastuzumab in HER2+ gastric cancer. Clin Cancer Res. 2018;24(5):1082–9.

Article  CAS  PubMed  Google Scholar 

Hudis C, Swanton C, Janjigian YY, Lee R, Sutherland S, Lehman R, et al. A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors. Breast Cancer Res. 2013;15(6):R110.

Article  PubMed  PubMed Central  Google Scholar 

Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, et al. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. Breast Cancer Res Treat. 2016;155(3):521–30.

Article  CAS  PubMed  Google Scholar 

Chien AJ, Tripathy D, Albain KS, Symmans WF, Rugo HS, Melisko ME, et al. MK-2206 and standard neoadjuvant chemotherapy improves response in patients with human epidermal growth factor receptor 2-positive and/or hormone receptor-negative breast cancers in the I-SPY 2 trial. J Clin Oncol. 2020;38(10):1059–69.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, Zhou BP. Stabilization of snail by NF-κB is required for inflammation-induced cell migration and invasion. Cancer Cell. 2009;15(5):416–28.

Article  CAS  PubMed  PubMed Central  Google Scholar